Neuralexo LLC is organized around discovery and development of treatments for the protection of tissues at risk of ischemic injury (i.e. brain, heart, kidney). Indications include injury associated with cardiac surgery, transplantation, traumatic brain injury and stroke. principals of the firm seek to develop new therapeutics to reduce the extent of damage and functional impairment resulting from these tyes of injury - an area of significant unmet medical need. Research indicates that activation of IRF transcription factors following stroke may be a viable therapeutic intervention for the treatment of stroke patients. Neuralexo is working to identify compounds with acceptable target specification optimize these compounds through hit to lead protocols and ultimately test for efficacy in a mouse model of cerebral ischemic injury.
